Biblio

Found 25 results
Filters: Keyword is Breast Neoplasms  [Clear All Filters]
2024
Nwakasi C, Esiaka D, Chinelo N, Ahmed S. How will I live this life that I'm trying to save? Being a female breast cancer survivor in Nigeria. Ethn Health. 2024 ;29(2):147-163.
James JElyse, Riddle L, Koenig B, Joseph G. Moving toward Equity through Embedded ELSI Ethnography. Hastings Cent Rep. 2024 ;54 Suppl 2:S93-S101.
Chidebe RCW, Orjiakor TC, Okwu GC, Orji M-GA, Nwosu-Zitta TO, Agha AA, Aruah SC, Okem-Akwiwu C, Nwakasi CC, Gyimah AAdjei, et al. "Not even my husband knows that I have this [breast cancer]": survivors' experiences in accessing, navigating and coping with treatment. Support Care Cancer. 2024 ;32(2):112.
2023
Parker BA, Shatsky RA, Schwab RB, Wallace AM, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, Veer LJ van 't, Ghia EM, et al. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. Breast Cancer Res Treat. 2023 ;199(2):281-291.
Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SE. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. J Urol. 2023 ;209(1):49-57.
Magbanua MJesus M, Veer Lvan 't, Clark AS, A Chien J, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, et al. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Res Treat. 2023 ;198(2):383-390.
Mukhtar RA, Esserman LJ. Time to Surgery in Breast Cancer-Is Faster Always Better?. JAMA Surg. 2023 ;158(5):492-493.
Esserman LJ, Ali H, McKenzie T. When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node. J Clin Oncol. 2023 ;41(12):2144-2150.
2022
Mukhtar R, W Symmans F, Esserman LJ. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply. JAMA Oncol. 2022 ;8(4):1.
Osdoit M, Yau C, W Symmans F, Boughey JC, Ewing CA, Balassanian R, Chen Y-Y, Krings G, Wallace AM, Zare S, et al. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 ;157(11):1034-1041.
Johansson A, Yu NY, Iftimi A, Tobin NP, Veer Lvan 't, Nordenskjöld B, Benz CC, Fornander T, Perez-Tenorio G, Stål O, et al. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature. Int J Cancer. 2022 ;150(12):2072-2082.
Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, et al. Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer. Tomography. 2022 ;8(3):1208-1220.
A Chien J, Kyalwazi B, Esserman LJ. Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting. Cell Rep Med. 2022 ;3(6):100664.
Cardozo JMNLopes, Drukker CA, Rutgers EJT, Schmidt MK, Glas AM, Witteveen A, Cardoso F, Piccart M, Esserman LJ, Poncet C, et al. Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. J Clin Oncol. 2022 ;40(12):1335-1345.
James JElyse, Riddle L, Caruncho M, Koenig BAnn, Joseph G. A qualitative study of unaffected ATM and CHEK2 carriers: How participants make meaning of 'moderate risk' genetic results in a population breast cancer screening trial. J Genet Couns. 2022 ;31(6):1421-1433.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRong Evely, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 ;40(6):609-623.e6.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy A-S, Laé M, Reyal F, Sonke GS, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 ;23(1):149-160.
Marczyk M, Mrukwa A, Yau C, Wolf D, Chen Y-Y, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, et al. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 ;33(8):814-823.
Johansson A, Dar H, Veer LJ van 't, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, et al. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial. J Clin Oncol. 2022 ;40(35):4071-4082.
Noordhoek I, Bastiaannet E, de Glas NA, Scheepens J, Esserman LJ, Wesseling J, Scholten AN, Schröder CP, Elias SG, Kroep JR, et al. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study. J Geriatr Oncol. 2022 ;13(8):1172-1177.
Esserman LJ, Parker BA, LaCroix AZ. Why It Is Time to Challenge Entrenched Beliefs About Breast Cancer Screening. J Womens Health (Larchmt). 2022 ;31(7):903-904.
2021
Cadet T, Burke SL, Naseh M, Grudzien A, Kozak RShoaf, Romeo J, Bullock K, Davis C. Examining the Family Support Role of Older Hispanics, African Americans, and Non-Hispanic Whites and Their Breast Cancer Screening Behaviors. Soc Work Public Health. 2021 ;36(1):38-53.
James JElyse, Riddle L, Koenig BAnn, Joseph G. The limits of personalization in precision medicine: Polygenic risk scores and racial categorization in a precision breast cancer screening trial. PLoS One. 2021 ;16(10):e0258571.
Wang T, Huilgol YS, Black J, D'Andrea C, James J, Northrop A, Belkora J, Esserman LJ. Pre-Appointment Nurse Navigation: Patient-Centered Findings From a Survey of Patients With Breast Cancer. Clin J Oncol Nurs. 2021 ;25(5):E57-E62.
2020
Glaser J, Coulter YZ, Thompson-Lastad A, Castro-Smyth L, Serrano E, Adler SR. Experiences of Advanced Breast Cancer Among Latina Immigrants: A Qualitative Pilot Study. J Immigr Minor Health. 2020 ;22(6):1287-1294.